NASH Drug Pipeline Shows Promise as 95+ Companies
Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
“Nonalcoholic Steatohepatitis (NASH) Pipeline Insight, 2020” by DelveInsight details the NASH pipeline landscape, unmet needs, and therapeutic assessment of key candidates. Over 95 companies, including AstraZeneca, Eli Lilly, Pfizer, and East Asian innovators like LG Chem, Shionogi, and Polaris Group, are advancing treatments. The market boasts a vast pipeline with pivotal trials, NMEs, and 90+ therapies in clinical development, such as GB1211, AZD2693, Tropifexor (LJN452), GSK4532990, and LG-1253.
Pipeline profiles include development status, phases, mechanisms, routes, companies, NME details, designations, drivers, and barriers. NASH involves fatty liver inflammation leading to scarring, with symptoms like fatigue and upper abdominal pain. No standard treatments exist; lifestyle changes help manage progression.
Get access to NASH Treatment Pipeline Sample Report
ENYO Pharma's EYP001, an oral non-steroidal FXR agonist, targets NASH by disrupting FXR-HBx interactions. It excels in STAM mouse model for fibrosis, steatosis, inflammation, ballooning, triglycerides, and NAS, with superior C4/FGF19 balance.
To learn more about NASH Drugs Development, request NASH Treatment Pipeline Sample Report
Global coverage spans 95+ companies: 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Akero Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Ascletis Pharma Inc, Zhejiang Doer Biologics Corp, Asdera LLC, Assembly Biosciences Inc, AstraZeneca Plc, Auransa Inc, Avaliv Therapeutics Inc, Avolynt Inc, ChemoCentryx Inc, ChemomAb Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc, EncuraGen Inc, Engitix Ltd, Hepion Pharmaceuticals Inc, Heprotech Inc, Hinova Pharmaceuticals Inc, HK inno.N Corp, HotSpot Therapeutics Inc, Ildong Pharmaceutical Co Ltd, Imago Pharmaceuticals Inc, ImmuneMed Inc, Immupharma Plc, Immuron Ltd, Indalo Therapeutics Inc, Inmune Bio Inc, Innovimmune Biotherapeutics Inc, Inorbit Therapeutics AB, Integral Molecular Inc, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, InventisBio Inc, Inventiva, LG Chem Ltd, LifeMax Laboratories Inc, Metabolys SAS, Metacrine Inc, Pattern Therapeutics, PegBio Co Ltd, Pfizer Inc, RadBio, Redx Pharma Plc, Regenasome Pty Ltd, Regulus Therapeutics Inc, SparkBioPharma Inc, SteroTherapeutics LLC, T3D Therapeutics Inc, TaiwanJ Pharmaceuticals Co Ltd, Thoth Science Inc, Wave Life Sciences Ltd, Xenexus Pharmaceuticals Pty Ltd, Xfibra Inc, XORTX Therapeutics Inc, YD Life Science Co, Yuhan Corp, Zebra Discovery Ltd, and more.
Get access to NASH Treatment Pipeline Sample Report
Key drugs: 90+ including GB1211, AZD2693, Tropifexor (LJN452), ORMD-0801, ZSP1601, EYP001a, Miricorilant, MK-3655, BMS-986263, Tirzepatide, BFKB8488A, TERN-101, Namodenoson, Leronlimab, PXL065, LPCN 1144, EFX, SNP-610, NGM282, Obeticholic acid, LYS006, ALN-HSD, PF-06865571, SEL.
Phases cover late-stage (Phase III), Phase II, Phase I, preclinical, inactive/discovery. Targets: protease, immune system, multiple kinase. Mechanisms: protease inhibitor, immunomodulatory, kinase inhibitor. Molecule types: small molecule, stem cell, gene therapy. Routes: inhalation, intravenous, oral, subcutaneous. Products: mono, combination.
East Asian highlights: Japan’s GSK K.K. (GSK4532990, Phase 2b, metabolic modulation, NCT05583344, Japanese sites); Astellas (FXR agonists, Phase 1-2); Shionogi (S-005151, Phase 1-2 anti-fibrotic). Korea’s Celltrion (CT-P biologics, preclinical/Phase 1); Daewoong (UDCA derivatives, Phase 1-2); LG Chem (LG-1253, Phase 2 FXR); JD Bioscience (GM-60106, Phase 1 HTR2A). Taiwan’s Polaris (ADI-PEG 20, Phase 2, NCT05842512); Taiwan Liposome (delivery systems, preclinical/Phase 1).